Single-cell sequencing methods have enabled multi-modal characterization of tumor heterogeneity and yielded novel insights into tumor evolution, therapeutic response and resistance, and measurable residual disease (MRD). Aaron Llanson, DIrector of Market Development at Mission Bio, gives an overview of the Tapestri Platform and showcases the novel capability to co-detect SNVs, indels, CNVs, and immunophenotypes from the same cell with a single, high-throughput workflow. Single-cell multi-modal sequencing unlocks the ability to truly understand clonal architecture and resolve tumor heterogeneity.
